Rare primary gastric peripheral T-cell lymphoma not otherwise specified: A case report

Table 1 Treatment approaches and outcomes for primary gastric T-cell lymphoma: Summary of literatures

Ref.	Study period (year)	Study type	Sample size	Patients with gastric peripheral T-cell lymphoma-not otherwise specified	Patient demographics	Treatment	Outcomes
Park et al[9]	1990-2004	Primary gastric lymphoma of T-cell origin	17	7 (41.1)	Median age 49 years, male (14 : 3)	CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide, Vanderbilt regimen, surgical resection	Median progression-free survival 10 months, median OS 12 months
Kim et al[8]	1995-2008	Endoscopic and clinical analysis of primary T-cell lymphoma of the GI tract	36	5 (13.9)	Median age 50 years, male to female ratio 2.6:1	Of the 36 patients, primary surgical resection with chemotherapy (55%), primary chemotherapy without surgery (45%)	Median OS 7.8 months, 3-year survival rate 19.4%
Kohri et al[10]	2007-2018	Peripheral T-cell lymphoma with GI involvement	11	2 (2.4)	Median age 75 years, 10 males and 1 female	CHOP	OS 7 months and 83 months (2 patients)
Zhang et al[5]	1975-2016	Gastric T-cell lymphoma in the SEER program	164	104 (63.4)	Median age 65 years, mostly White and male	Chemotherapy, surgery, radiotherapy	Median OS 8 months, 5-year OS 23.5%

CHOP: Cyclophosphamide, doxorubicin, vincristine, and prednisone; GI: Gastrointestinal; OS: overall survival.